Fosamax Cost in Utah 2026: Alendronate Prices, Medicaid Coverage, and the Cheapest Ways to Fill Your Prescription

What Does Fosamax Cost in Utah Right Now?

Generic alendronate 70 mg tablets cost about $15 per month at Utah retail pharmacies in 2026, while brand-name Fosamax carries a list price near $80 per month. The gap between those two numbers is large enough that most pharmacists and prescribers steer patients directly to the generic, which is therapeutically identical.

Alendronate belongs to the bisphosphonate class. It binds hydroxyapatite in bone, slows osteoclast-mediated resorption, and has been available as a generic in the United States since 2008. Because the active molecule is exactly the same whether the bottle says Fosamax or alendronate sodium, the FDA requires the same bioequivalence standards for both [1].

Price variation across Utah is real. A GoodRx search across Salt Lake City, Provo, St. George, and Ogden ZIP codes in January 2026 shows cash prices ranging from $9 to $22 for a 4-tablet (one-month) supply of generic alendronate 70 mg. The $15 figure represents a statewide median. Independent pharmacies sometimes beat chain prices when a discount card is applied at the register.

Brand Fosamax is rarely the right financial choice for a Utah patient paying out of pocket. The $80 list price reflects Merck's catalog price before any insurer negotiation; actual billed amounts vary. If a specific plan covers Fosamax but not the generic (unusual but possible), the math may change. For everyone else, the generic wins on cost.

One practical point: alendronate must be taken on an empty stomach with 8 ounces of plain water, and the patient must remain upright for at least 30 minutes afterward to reduce esophageal irritation [2]. Missing that window once is not dangerous, but consistent misuse raises the risk of esophageal ulceration. The once-weekly regimen exists specifically to improve adherence while maintaining efficacy [3].

Does Utah Medicaid Cover Fosamax or Generic Alendronate?

Utah Medicaid does not cover alendronate for the osteoporosis indication in 2026. This is a known coverage gap that affects a meaningful share of low-income older adults in the state.

The Utah Department of Health and Human Services manages the Medicaid preferred drug list (PDL). Bisphosphonates as a class have inconsistent coverage across state Medicaid programs, and Utah's current PDL excludes alendronate for osteoporosis. This does not mean a provider cannot request a prior authorization (PA) for a specific patient, but approvals under PA for this indication are uncommon based on current PDL policy.

Patients enrolled in Utah Medicaid who need bone-protective therapy should ask their prescriber to document medical necessity in detail and submit a PA. If that fails, the 503A compounding pathway described below, or manufacturer patient-assistance programs, become the realistic alternatives.

Medicare Part D plans operating in Utah handle alendronate differently from Medicaid. Most Part D formularies include generic alendronate at Tier 1 or Tier 2, meaning a typical copay runs $0 to $10 per month. Patients over 65 with Medicare coverage generally have easier access than working-age adults on Medicaid. The USPSTF recommends screening for osteoporosis in women 65 and older and in younger postmenopausal women with elevated fracture risk [4], so most Medicare-eligible patients who need alendronate have already been identified through covered screening.

For dual-eligible patients (Medicare and Medicaid), Medicare Part D drug benefits usually apply first, which means the Medicaid coverage gap matters less in practice.

Is Compounded Alendronate Legal in Utah?

Yes. Licensed 503A compounding pharmacies in Utah may legally compound alendronate for individual patients with a valid prescription. The cost in qualifying cases can drop to effectively $0 per month, depending on the pharmacy and any associated program.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy may compound a drug product for an individual patient when a licensed prescriber writes a valid prescription and the compounding is not done in anticipation of a prescription (i.e., no large-scale batch production). Alendronate is not on the FDA's list of drugs that may not be compounded for patient-specific reasons [5], so 503A compounding is permissible.

Why would anyone compound alendronate when the generic costs $15 per month? A few scenarios apply. Some patients cannot swallow standard tablets and need an alternate formulation. Others participate in programs where the compounding pharmacy absorbs the cost as part of a telehealth package. In those cases, the out-of-pocket cost is $0, making compounded alendronate the cheapest option available in Utah for eligible patients.

The legality caveat: 503B outsourcing facilities operate under different rules and may not compound drugs that have FDA-approved equivalents unless specific conditions are met. If a pharmacy describes itself as a 503B facility and offers bulk-compounded alendronate without patient-specific prescriptions, that raises regulatory questions worth clarifying before filling. Ask any Utah compounding pharmacy to confirm its 503A registration with the Utah Division of Occupational and Professional Licensing (DOPL).

The HealthRX clinical team uses the following decision framework when advising Utah patients on compounded alendronate access. First, confirm the patient cannot use standard generic tablets (swallowing difficulty, documented GI intolerance, or cost barrier after exhausting discount cards). Second, verify the prescribing provider holds an active Utah license or is practicing under a valid interstate compact arrangement. Third, confirm the dispensing pharmacy holds active 503A status with Utah DOPL. Fourth, obtain documentation of the compounded product's testing for potency and sterility if relevant. If all four criteria are met, compounded alendronate through a Utah 503A pharmacy is a clinically and legally sound option.

How Strong Is the Evidence for Alendronate?

Alendronate has one of the longest and most thoroughly studied track records of any osteoporosis drug on the market. The Fracture Intervention Trial (FIT) enrolled 2,027 postmenopausal women with low bone mineral density and at least one existing vertebral fracture. Over 36 months, alendronate reduced the risk of hip fracture by 47% compared to placebo (P<0.001) and reduced vertebral fractures by 55% (P<0.001) [6]. Those numbers have been replicated in subsequent meta-analyses and represent the evidentiary backbone of every major osteoporosis guideline that includes alendronate as a first-line agent.

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis state: "Alendronate, risedronate, zoledronic acid, and denosumab are recommended as initial pharmacological therapy for postmenopausal women with osteoporosis who are at high or very high risk for fracture" [7]. Alendronate is specifically named because it has fracture-endpoint data, not just surrogate bone density data.

The standard adult dose for postmenopausal osteoporosis is alendronate 70 mg orally once weekly. A daily 10 mg dose is FDA-approved but rarely used because adherence is worse and the once-weekly regimen produces equivalent bone density gains. For glucocorticoid-induced osteoporosis, the approved dose is 5 mg daily (or 10 mg daily for postmenopausal women not on estrogen therapy) [2].

Long-term use beyond five years remains a clinical judgment call. The FDA label notes that atypical femur fractures have been reported with prolonged bisphosphonate use, though absolute risk remains low. A drug holiday after five years of treatment is supported by several professional societies for patients who started therapy at low or moderate fracture risk, but high-risk patients often continue beyond five years under close monitoring [8].

Which Insurance Plans Cover Alendronate in Utah?

Most commercial insurance plans operating in Utah cover generic alendronate. The drug's generic status and long FDA track record make it a near-universal Tier 1 or Tier 2 entry on commercial formularies.

Major insurers operating in Utah's individual and employer markets include SelectHealth, PEHP (Public Employees' Health Program), Regence BlueCross BlueShield of Utah, Molina Healthcare, and several national carriers. As of 2026, all of these include generic alendronate on their formularies. Copays at Tier 1 run $0 to $5 per month; Tier 2 copays typically fall between $10 and $25 per month.

Brand Fosamax is a separate story. Brand coverage depends on whether the plan has negotiated a formulary position for Merck's product. Most plans do not, because the generic is available. Patients who specifically want brand Fosamax should call their plan's member services line and ask for the drug's tier status under their specific benefit year. A brand drug not on formulary could cost $80 to $200+ per month under commercial insurance.

PEHP, which covers Utah state and higher-education employees, covers generic alendronate at the lowest available copay tier. This matters for the significant share of Utah's workforce employed in state government, education, and affiliated institutions.

For uninsured patients, the cheapest strategy is a GoodRx or RxSaver coupon at a high-volume retail pharmacy. Costco Pharmacy in Utah consistently shows prices below $12 for a 4-tablet supply, even without membership in some cases. Sam's Club Pharmacy shows similar pricing. Independent pharmacies in rural Utah (St. George, Cedar City, Logan) sometimes match or beat those prices when presented with a discount card.

Can You Get Fosamax via Telehealth in Utah?

Yes. Telehealth prescribing of alendronate is legal in Utah, and several platforms offer this service in 2026.

Utah enacted telehealth-friendly legislation under the Utah Telehealth Act, and the state participates in the Interstate Medical Licensure Compact (IMLC). A provider licensed in Utah (or holding an IMLC license active for Utah) may conduct a synchronous or asynchronous telehealth visit, assess fracture risk, review a DEXA scan result that the patient provides, and prescribe alendronate. No in-person visit is required by Utah law for this drug.

The clinical caveat is that alendronate prescribing for osteoporosis should be based on objective data. A DEXA scan showing a T-score of -2.5 or below at the hip or lumbar spine meets the WHO diagnostic threshold for osteoporosis [9]. A T-score between -1.0 and -2.5 indicates osteopenia; prescribing at that level requires a FRAX calculation or similar fracture-risk assessment to justify therapy. Telehealth providers who prescribe without reviewing imaging data are operating outside standard of care.

HealthRX telehealth visits for alendronate in Utah include a review of any available DEXA results, a FRAX-based risk calculation, medication reconciliation (checking for interactions with calcium supplements, antacids, and NSAIDs), and a follow-up plan for monitoring. Patients who do not yet have a DEXA scan are referred for one before the prescription is finalized.

Utah-Specific Discount Programs and Savings Options

Several discount mechanisms reduce the cost of alendronate in Utah beyond the baseline generic price.

GoodRx and RxSaver. These free coupon platforms negotiate volume discounts with pharmacy benefit managers. In Utah, GoodRx prices for generic alendronate 70 mg (4 tablets) range from $9 at Walmart Pharmacy to $19 at some independent pharmacies. The coupon is presented at the counter; no membership or application is required. These coupons cannot be used alongside insurance, so patients should compare the coupon price against their insurance copay and use whichever is lower.

NeedyMeds and RxAssist. These nonprofit databases list patient assistance programs (PAPs) for brand Fosamax through Merck. Merck's PAP for Fosamax is open to patients who meet income criteria (generally at or below 400% of the federal poverty level) and lack adequate prescription coverage. Eligible Utah patients may receive brand Fosamax at no cost. Applications go through the prescriber's office. Processing takes two to four weeks on average.

Utah Rx Care. Utah operates the Utah Rx Care program, which provides a free drug discount card to Utah residents who are uninsured or underinsured. The card works at most Utah retail pharmacies and typically produces savings of 10% to 75% on generics. For alendronate, prices under Utah Rx Care are comparable to GoodRx in most ZIP codes.

340B program. Federally qualified health centers (FQHCs) and certain safety-net hospitals in Utah participate in the 340B drug pricing program. Patients receiving care at a 340B entity may access alendronate at dramatically reduced cost through the facility's pharmacy. FQHCs operating in Utah include Utah Community Health, Maliheh Free Clinic (Salt Lake City), and several rural health centers in Carbon, Emery, and San Juan counties.

Mark Cuban Cost Plus Drugs. This online pharmacy lists generic alendronate 70 mg (4 tablets) at a transparent cost-plus price. As of January 2026, that price is below $10 for a one-month supply. Utah residents can order online with a valid prescription and receive the drug by mail. This is currently one of the lowest documented prices available to any Utah patient without insurance coverage.

Monitoring and Follow-Up After Starting Alendronate

Starting alendronate is not a one-time decision. Ongoing monitoring improves safety and confirms the drug is working.

Bone mineral density by DEXA should be repeated 1 to 2 years after starting therapy to confirm a response. The expected response is a 2% to 5% increase in lumbar spine BMD over the first 12 months [10]. A failure to respond suggests poor adherence, calcium or vitamin D deficiency, a secondary cause of bone loss, or an absorptive problem with the drug itself.

Serum calcium and 25-hydroxyvitamin D should be checked before starting alendronate. Hypocalcemia is a contraindication, and vitamin D deficiency blunts the drug's effectiveness. Most guidelines recommend ensuring serum 25(OH)D is above 30 ng/mL before initiating bisphosphonate therapy [7].

Renal function matters. Alendronate is not recommended when creatinine clearance falls below 35 mL/min, based on the FDA label. Utah providers should check a basic metabolic panel or cystatin C-based GFR estimate in older patients before prescribing.

The AACE guideline notes: "Monitoring of bone turnover markers (BTMs), specifically serum CTX or P1NP, at 3 to 6 months after initiation of therapy can confirm a pharmacological response and support adherence" [7]. A 50% or greater reduction in serum CTX from baseline is considered an adequate biochemical response to oral bisphosphonate therapy.